Technical Reports on Biotech Stocks -- Juno Therapeutics, Immunomedics, Cempra, and Neuralstem

Tuesday, November 29, 2016 General News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, November 29, 2016 /PRNewswire/ --

This morning, revisits the Biotech industry, focusing

on the performances of the following companies: Juno Therapeutics Inc. (NASDAQ: JUNO), Immunomedics Inc. (NASDAQ: IMMU), Cempra Inc. (NASDAQ: CEMP), and Neuralstem Inc. (NASDAQ: CUR). The iShares Nasdaq Biotechnology ETF (IBB) is up 7% this month, as
policy uncertainty and fear of stricter regulations have waned since Trump's victory. Download the free research reports on these stocks today:

Juno Therapeutics

Shares in Seattle, Washington headquartered Juno Therapeutics Inc. ended Monday's session at $22.12, which was a drop of 3.87%. The stock recorded a trading volume of 2.90 million shares, which was above its three months average volume of 1.78 million shares. The Company's shares are trading 21.90% below their 50-day moving average. Moreover, shares of Juno Therapeutics, which engages in developing cell-based cancer immunotherapies, have a Relative Strength Index (RSI) of 34.69.

On November 23rd, 2016, Juno Therapeutics announced that it has voluntarily placed on hold the Phase II clinical trial of JCAR015 in adult patients with relapsed or refractory B cell acute lymphoblastic leukemia, known as the "ROCKET" trial. The clinical hold was initiated after two patients suffered cerebral edema earlier this week. One patient died and as of last night the other is not expected to recover.

On November 25th, 2016, research firm SunTrust downgraded the Company's stock rating from 'Buy' to 'Hold'. The research firm also revised downwards its previous target price from $48 to $25. See our free and comprehensive research report on JUNO at:


Morris Plains, New Jersey headquartered Immunomedics Inc.'s stock declined 3.17%, closing the day at $3.36, with a total trading volume of 1.58 million shares. The Company's shares have advanced 53.42% in the last month, 23.99% in the previous three months, and 9.45% on an YTD basis. The stock is trading 23.42% and 17.38% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Immunomedics, which focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases, have an RSI of 67.76.

On November 28th, 2016, Immunomedics announced that, after careful consideration and in light of venBio Select Advisors LLC's recently nominated slate of four director candidates to the Company's five-member Board, the Board of Directors has determined that the postponement of the Company's 2016 Annual Meeting of Stockholders for a short period is necessary and in the best interest of its stockholders. The Board believes that before voting at the Company's 2016 Annual Meeting, it is important that stockholders have the opportunity to consider the Company's progress toward achieving a number of critical near-term milestones. IMMU free research report PDF is just a click away at:


On Monday, shares in North Carolina headquartered Cempra Inc. recorded a trading volume of 1.02 million shares. The stock ended the day 2.27% lower at $6.45. The Company's shares are trading below their 50-day moving average by 63.94%. Furthermore, shares of Cempra, which focuses on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases in North America, have an RSI of 21.50.

On November 04th, 2016, Cempra announced that the majority of the FDA's Antimicrobial Drugs Advisory Committee (AMDAC) voted (7-6) that efficacy results of Cempra's solithromycin outweigh the risks for the treatment of community-acquired bacterial pneumonia (CABP). Members of AMDAC voted unanimously (13-0) that there was substantial evidence of the efficacy of solithromycin for CABP. The committee also voted (12-1) that the risk of hepatotoxicity with solithromycin had not been adequately characterized and discussed a variety of potential approaches to further characterize the existing liver safety information on solithromycin.

On November 11th, 2016, research firm Needham downgraded the Company's stock rating from 'Buy' to 'Hold'. Sign up for your complimentary report on CEMP at:


Germantown, Maryland headquartered Neuralstem Inc.'s stock rose 1.44%, finishing yesterday's session at $0.28, with a total trading volume of 375,594 shares. The Company's shares have advanced 12.80% in the last one month and 4.44% over the previous three months. The stock is trading below its 50-day moving average by 2.21%. Additionally, shares of Neuralstem, which focuses on the research, development, and commercialization of central nervous system therapies based on its proprietary human neuronal stem cells and stem-cell derived small molecule compounds, have an RSI of 52.05.

On November 07th, 2016, research firm Aegis Capital initiated a 'Buy' rating on the Company's stock.

On November 08th, 2016, Neuralstem reported Q3 2016 revenue of $2,500, same as revenue of $2,500 in Q3 2015. The company's Research and Development expenses increased approximately $198,000, or 6%, for Q3 2016 compared to Q3 2015. Other expenses, net totaled were approximately $303,000 and $440,000 for Q3 2016 and Q3 2015, respectively. Register for free on and download the latest research report on CUR at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store